What Does Viatris’ Trio Of Attacks On US Semaglutide Mean For Wegovy Generics?

Viatris’ Spate Of Inter Partes Reviews Largely Denied, With One Upside For Firm

Viatris has failed in its attempt to begin proceedings to overturn two key semaglutide patents in the US, while succeeding on another, as part of its bid to gain early entry with its proposed generic version of Novo Nordisk’s renowned Wegovy. Generics Bulletin reviews the landscape.

Novo Nordisk
• Source: Shutterstock

A US patent tribunal office has refused Viatris’ requests to invalidate two US semaglutide composition patents, the active ingredient in Novo Nordisk’s renowned Wegovy treatment for obesity among other of the Danish originator’s major brands, raising the potential for generic competition to be pushed out until the early 2030s.

In two separate petitions, Viatris had requested the US Patent and Trademark Office’s Patent Trial Appeal Board to institute an...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin